Coronavirus disease 2019 associated pulmonary mucormycosis
Infection
.
2023 Oct;51(5):1601-1602.
doi: 10.1007/s15010-023-02038-3.
Epub 2023 Apr 17.
Authors
Manoj Kumar Panigrahi
1
,
Pratima Singh
2
,
Pritinanda Mishra
3
,
Gopal Durgeshwar
4
Affiliations
1
Department of Pulmonary Medicine & Critical Care, All India Institute of Medical Sciences, Bhubaneswar, 751019, India.
[email protected]
.
2
Department of Pulmonary Medicine, Kalinga Institute of Medical Sciences, Bhubaneswar, India.
3
Department of Pathology & Laboratory Medicine, All India Institute of Medical Sciences, Bhubaneswar, India.
4
Department of Pulmonary Medicine & Critical Care, All India Institute of Medical Sciences, Bhubaneswar, 751019, India.
PMID:
37067756
PMCID:
PMC10106873
DOI:
10.1007/s15010-023-02038-3
No abstract available
MeSH terms
Antifungal Agents / therapeutic use
COVID-19* / complications
Humans
Mucormycosis* / complications
Mucormycosis* / diagnosis
Mucormycosis* / drug therapy
Substances
Antifungal Agents